These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 1846549)

  • 1. Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo.
    Chaplin DJ; Horsman MR; Aoki DS
    Br J Cancer; 1991 Jan; 63(1):109-13. PubMed ID: 1846549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
    Holden SA; Herman TS; Teicher BA
    Radiother Oncol; 1990 May; 18(1):59-70. PubMed ID: 2113698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice.
    Fingar VH; Mang TS; Henderson BW
    Cancer Res; 1988 Jun; 48(12):3350-4. PubMed ID: 3130983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.
    Chaplin DJ; Horsman MR; Siemann DW
    Br J Cancer; 1993 Aug; 68(2):269-73. PubMed ID: 8347481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of misonidazole, etanidazole, or hyperthermia to treatment with fluosol-DA/carbogen/radiation.
    Teicher BA; Herman TS; Holden SA; Jones SM
    J Natl Cancer Inst; 1989 Jun; 81(12):929-34. PubMed ID: 2525198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing.
    Teicher BA; Holden SA; Rose CM
    Int J Cancer; 1985 Nov; 36(5):585-9. PubMed ID: 3932225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of carbogen and nicotinamide on intravascular oxyhaemoglobin saturations in SCCVII and KHT murine tumours.
    Fenton BM
    Br J Cancer; 1995 May; 71(5):945-9. PubMed ID: 7734318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing.
    Siemann DW; Horsman MR; Chaplin DJ
    Radiother Oncol; 1994 May; 31(2):117-22. PubMed ID: 8066190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
    Teicher BA; Herman TS; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity.
    Teicher BA; Holden SA; Jacobs JL
    Cancer Res; 1987 Jan; 47(2):513-8. PubMed ID: 3098413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
    Teicher BA; Holden SA; Northey D; Dewhirst MW; Herman TS
    Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):103-9. PubMed ID: 8482616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased radiosensitivity of tumors by perfluorochemicals and carbogen.
    Song CW; Zhang WL; Pence DM; Lee I; Levitt SH
    Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1833-6. PubMed ID: 3930442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinamide and carbogen: major effect on the radiosensitivity of EMT6 and HRT18 tumours.
    Simon JM; Lartigau E; Guichard M
    Radiother Oncol; 1993 Sep; 28(3):203-7. PubMed ID: 8255997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion.
    Rockwell S; Mate TP; Irvin CG; Nierenburg M
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1315-8. PubMed ID: 3093416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in tumor pO2 by perfluorochemicals and carbogen.
    Hasegawa T; Rhee JG; Levitt SH; Song CW
    Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):569-74. PubMed ID: 3104250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents.
    Teicher BA; Holden SA
    Cancer Treat Rep; 1987 Feb; 71(2):173-7. PubMed ID: 3100035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of various oxygenation conditions and fluosol-DA on cytotoxicity and antitumor activity of bleomycin in mice.
    Teicher BA; Holden SA; Cathcart KN; Herman TS
    J Natl Cancer Inst; 1988 Jun; 80(8):599-603. PubMed ID: 2453675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.
    Kim GE; Song CW
    Cancer Chemother Pharmacol; 1989; 25(2):99-102. PubMed ID: 2513138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.